IsoPSA Performance Characteristics Are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results from the IsoPSA Validation Study

The study titled "IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study" concludes that the diagnostic performance of IsoPSA, a test used for detecting prostate cancer, remains consistent regardless of the use of 5-alpha reductase inhibitors (5-ARI) and alpha-blockers, which are medications commonly prescribed for benign prostatic hyperplasia. This finding is significant as it suggests that patients undergoing treatment with these medications can still rely on IsoPSA for accurate detection of any prostate cancer, including clinically actionable cases, without interference from their medication regimen.